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Background: Efavirenz is now a first‑line non‑nucleoside reverse transcriptase inhibitor used as highly active antiretroviral 
therapy (HAART) though its use is fraught with maternal side effects, usually of the central nervous system (CNS) and fetal 
complications.
Objective: The study aims to comparatively document the maternal side‑effect profile of an efavirenz‑containing fixed‑dosage 
HAART and compliance with its use in HIV‑positive pregnant and nonpregnant women at the Lagos University Teaching 
Hospital (LUTH), Idi‑Araba.
Methodology: A prospective study among HIV‑positive pregnant (40) and nonpregnant women (40) on efavirenz‑containing 
fixed‑dose HAART (Atripla®) who were recruited purposively at the antenatal clinic and AIDS Prevention Initiative Nigeria (APIN) 
clinics of LUTH. Data analysis was done with EPI Info 2014, and the results are presented in frequencies.
Results: The mean age of respondents was 31 ± 5.7 years. Atripla® was the only fixed‑dose combination used. Fifty‑three 
percent and 62.5% of pregnant and nonpregnant HIV‑positive women, respectively, reported CNS side effects of Atripla® 
[odds ratio: 0.66, 95% confidence interval 0.27–1.62]. Adherence to the use of Atripla® was 100% among HIV‑positive 
pregnant women. Women with baseline viral load values greater than 400 copies/mL reported more side effects to Atripla®.
Conclusion: There are similar side‑effect profiles of Atripla® in HIV‑positive women irrespective of pregnancy. Education and 
counselling can help foster adherence, resulting in improved immunological and virological outcome.
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Introduction
HIV/AIDS continues to pose a significant public health 
challenge globally.[1] According to the Joint United Nations 
Programme on HIV/AIDS (UNAIDS), 36.9 million people 
were living with HIV in 2017, and out of these 1.8 million 
were children under the age of 15 years. In 2017, there 
were 1.8 million new HIV infections, with a decline of new 
HIV infection among children by 35%, compared with 2010 
figures.[2] Despite the reduction in new HIV infections, most 
infections in children (90%) are acquired by mother-to-child 
transmission.[3]
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To reduce the number of children affected or infected with 
HIV, the World Health Organization (WHO) and the UNAIDS 
have proposed a comprehensive approach consisting 
of four key strategies.[3] One of these is elimination of 
mother-to-child transmission (EMTCT) of HIV infection.[4] This 
is achievable through the use of highly active antiretroviral 
therapy (HAART), regarded as the single most important step 
in EMTCT.[1] Without any intervention, the risk of MTCT of HIV 
infection is 15%–45%.[1] Risk factors for vertical transmission 
include maternal progression of infection, assessed with 
peripheral viral load or clinical or immunological markers, 
prematurity, increased duration of ruptured membranes, 
presence of sexually transmitted infections, invasive 
procedures, mode of delivery, and breastfeeding.[1] The use 
of HAART and other components of the comprehensive 
approach to EMTCT could lower the risk to as low as 2%.[1] 
HAART also improves maternal health outcomes and reduces 
viral load.[1]
Efavirenz is a non-nucleoside reverse transcriptase 
inhibitor (NNRTI), which is now regarded by the WHO as 
the preferred first-line NNRTI.[4] Prior to 2013, the use of 
efavirenz in pregnant women was restricted due to a potential 
concern over teratogenicity, especially in the first trimester 
based on animal trials.[5,6] However, a programmatic update 
on HAART for pregnant women by WHO recommends 
efavirenz-based regimen for EMTCT.[7] This is because of the 
advantage of once-daily, fixed-dose combination (FDC) of 
tenofovir, lamivudine or emtricitabine, and efavirenz. It also 
allows the streamlining of antiretroviral administration in 
resource-constrained settings such as ours. Other advantages 
include antiviral potency, relative low frequency of severe 
adverse effects, a greater likelihood of adherence, and efficacy 
against hepatitis B virus.[8,9]
In addition, efavirenz is more cost-effective in direct comparison 
to nevirapine, and less likely to be associated with antiviral 
resistance.[9] Also, hepatotoxicity associated with nevirapine 
is unknown with efavirenz. Better viral load reduction, a 
lower incidence of AIDS-defining illnesses, and a 12-month 
increase in CD4 count are other benefits of efavirenz.[10,11] 
Despite the proven benefits of efavirenz use among pregnant 
HIV-positive women, certain adverse side effects have been 
associated with its use. A majority of these are central nervous 
system (CNS)-based and include hallucination, depression, 
insomnia, abnormal thinking, impaired concentration, 
confusion, loss of memory, euphoria, and suicidal ideation.[12-14] 
The side effects of efavirenz are associated with its plasma 
levels, hence stepwise dosing has been shown to decrease 
these side effects.[14] Another explanation for the occurrence 
of these side effects is genetic polymorphism. Efavirenz is 
metabolized mainly by the CYP450 enzyme system, and this 
enzyme is highly susceptible to genetic polymorphism, and 
polymorphs play a role in the variability of efavirenz plasma 
concentration.[1] This study is imperative because the side-effect 
profile of efavirenz use among HIV-positive pregnant women 
in our environment has not been documented. The objectives 
of this study were to identify the side-effect profile of Atripla® 
use among pregnant HIV-positive women and nonpregnant 
HIV-positive women at LUTH and assess the level of compliance 
and correlate compliance with immunologic suppression (viral 
load and CD4 cell count).
Methodology
Study area
The Lagos University Teaching Hospital (LUTH) is the 
teaching hospital of the College of Medicine of the 
University of Lagos. It was founded in 1962 and is situated 
in the heart of Lagos Mainland, which has population of 
over 2,150,100 inhabitants. It serves the whole of Lagos 
and its suburbs; and it is open to all categories of patients. 
The hospital operates at the tertiary level of the healthcare 
delivery system. Referrals are received from both private and 
public hospital in Lagos as well as other parts of the country.
LUTH’s Obstetrics and Gynaecology Department has a total 
of 134 beds, out of the hospital’s 720 beds. There are 74 
obstetric beds in three wards (wards C2, C3, and C4) and 
60 gynecological beds in two wards (wards B2 and C1). The 
neonatal unit/labor ward complex, which became operational 
in February 1987, houses the neonatal unit for babies 
delivered in LUTH and the labor wards unit under one roof. 
Also, within this complex are two standard operating theaters 
and four doctors’ rooms shared by resident obstetricians, 
anesthetists, and neonatologists. It affords maximal 
utilization of services since obstetricians, neonatologists, and 
anesthetists all work together in close proximity. It has 14 
delivery suites, two cardiotocography machines, 58 neonatal 
cots, including incubators, and two standard operating 
theaters. The hospital presently has an average of between 
1500 and 2500 deliveries annually.
Study population
The study included booked/unbooked pregnant women 
and nonpregnant women who registered with the AIDS 
Prevention Initiative Nigeria (APIN) center of LUTH and who 
are on efavirenz-containing HAART – Atripla®.
Study design
The study was a prospective study among pregnant and 
nonpregnant women taking efavirenz, who were selected in 
a purposive manner.
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Inclusion criteria
•	 Pregnant	 women	 taking	 efavirenz‑containing	
antiretroviral agent (Atripla) who registered with the 
APIN center in LUTH
•	 Nonpregnant	 women	 taking	 efavirenz‑containing	
antiretroviral agent (Atripla) who registered with the 
APIN center in LUTH.
Sample size
All HIV-positive pregnant women on efavirenz-containing 
regimens and a comparable number of HIV-positive 
nonpregnant women on efavirenz over a 6-month period 
were recruited for the study.
Data collection
The reason for this study with the procedure was explained 
to each of the respondent, and verbal consent was obtained 
thereafter. Data were obtained by the principal investigator 
through interviews using a pretested proforma. These 
included biodata, length of HIV diagnosis, duration of 
efavirenz use, drug compliance, side effects, and timing of 
side effects.
Data analysis
Data were inputted into an electronic database designed on 
Epi Info 2014, and analysis was carried out with the same 
statistical package. The results are presented in frequency 
tables and cross-tables. The association between categorical 
variables was tested using Chi-square, and differences in 
group means were assessed using t-test. A confidence interval 
of 95% was used with the level of significance set at a P value 
of ˂0.05.
Ethical consideration
The study was carried out after obtaining ethical approval 
from the Ethics Committee of the LUTH (Ref. No: ADM/
DCST/HREC/APP/710). The purpose and scope of this study 
were explained to the respondents and verbal consent was 
obtained before being recruited into the study. The rights 
of potential respondents to participate or decline were 
respected and kept confidential.
Results
A total of 80 women living with HIV completed the pretested, 
structured questionnaire. Forty of them were pregnant, while 
40 were nonpregnant. Their mean age was 31 ± 5.7 years. 
The demographic parameters of both groups are presented 
in Table 1.
Among pregnant women, 29 (72.5%) got diagnosed with 
HIV prior to getting pregnant, a majority of whom [(93.1%)] 
were diagnosed with HIV more than 2 years before the study. 
Many (26; 65%) pregnant women had commenced HAART for 
more than 2 years before pregnancy. Among all respondents, 
51 (63.8%) had been on Atripla for less than a year, and this 
included 30 (75.0%) pregnant women.
Compliance with the use of Atripla® according to institutional 
criteria (client’s self-reported usage and pill count) was 97.5% 
among all respondents. Pregnant women displayed a slightly 
higher level of compliance compared with nonpregnant 
women (97.5% vs. 95%). In assessing their level of compliance 
with the use of efavirenz according to institutional 
criteria (patient self-reporting and pill counting), 97.5% rate 
was obtained among all participants.
Forty-six (57.5%) women reported one or more side effects 
with the use of Atripla®. This occurred more in nonpregnant 
women [25 (62.5%)] when compared with pregnant 
women [21 (52.5%)] (odds ratio: 0.66, 95% confidence interval 
0.27–1.62). This is shown in Table 2.
The commonly reported side effects of Atripla® were 
drowsiness [18 (39.1%)], nightmares [14 (30.4%)], 
Table 1: Sociodemographic parameters of respondents on 
efavirenz
Variables Pregnant (n=40) Nonpregnant (n=40)
Age (years)
20‑24 1 (2.5%) 2 (5.0%)
25‑29 6 (15.0%) 4 (10.0%)
30‑34 19 (47.5%) 9 (22.5%)
≥35 14 (35.0%) 25 (62.5%)
Total 40 (100%) 40 (100%)
12.5%
0 13 (32.5%) 9 (22.5%)
1 10 (25.0%) 8 (20.0%)
2 12 (30.0%) 9 (22.5%)
3 3 (7.5%) 5 (12.5%)
4 2 (5.0%) 6 (15.5%)
5 0 (0%) 3 (7.5%)
Total 40 (100%) 40 (100%)
Education
None 1 (2.5%) 0 (0%)
Primary 5 (12.5% 0 (0%)
Secondary 10 (25.0%) 8 (20.0%)
Tertiary 23 (57.5%) 16 (40.0%)
Postgraduate 1 (2.5%) 16 (40.0%)
Total 40 (100%) 40 (100%)
Marital status
Single 7 (17.5%) 10 (25.0%)
Married 33 (82.5%) 25 (62.5%)
Divorced 0 (0%) 1 (2.5%)
Cohabitation 0 (0%) 4 (10.0%)
Total 40 (100%) 40 (100%)
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and insomnia [6 (13.0%)]. Other side effects were 
confusion [4 (8.7%)], loss of [memory (2.2%)], and skin 
rashes [(4.4%)] [Table 2]. Cross-tabulation done between age 
and occurrence of side effects among all respondents revealed 
more episodes of side effects in pregnant and nonpregnant 
women	age	≥35	years.	However,	this	was	not	statistically	
significant [Table 3a and b].
Only half of our pregnant participants had baseline viral load 
results, out of which 70% (14/20) had values greater than 
400 copies/mL. However, 6 months after commencement 
of Atripla®, 10 (50%) had viral load values greater than 
400 copies/mL [Tables 4a and 4b].
Among our nonpregnant participants, 15 (37.5%) had initial 
assessment of viral load, 3 (20%) of whom had viral load 
values	≤400	 copies/mL.	 Six	months,	 after	 commencing	
efavirenz therapy, 6 (40%) of these women had viral load 
values	≤400	copies/mL.	In	this	study,	a	baseline	viral	load	
of	<400	copies/mL	was	associated	with	the	development	of	
side effects among pregnant women taking Atripla.
Thirty-three (82.5%) pregnant women had both baseline and 
follow-up CD4 cell count results [Tables 5a and 5b].
Among nonpregnant respondents, 36 (90%) had initial CD4 
count results, with 13 (36.1%) having CD4 count values greater 
than 500 cells/mm3. The findings were similar following 
6 months on efavirenz therapy with 13 (36.1%) women having 
CD4 count values greater than 500 cells/mm3. This is depicted 
in Tables 6a and 6b.
Cross-tabulations between maternal side effects of efavirenz 
and baseline viral load with baseline CD4 count revealed 
pregnant respondents with CD4 cell count of ˂ 500 cells/mm3 
were more likely to develop side effects to Atripla®.
Discussion
This study provides information on the side-effect profile 
associated with the use of Atripla® an efavirenz-containing 
FDC HAART in HIV-positive pregnant women for EMTCT 
of HIV in a low-income country, as well as comparing the 
side-effect profile among nonpregnant women.
The frequency of adverse drug reaction related to the use 
of ARVs among pregnant women ranges between 5% and 
78% depending on the geographical region, social status, 
degree of immunodeficiency, and length of exposure 
to ARTs.[13] In this study, 52.5% of pregnant women on 
Atripla® reported side effects, with the main side effects 
being CNS-related ranging from insomnia to abnormal 
thinking. This is in keeping with several studies which 
show that the dominant side-effect profile associated 
with the use of efavirenz is CNS-related.[9,11,13-15] This is 
important because the development of side effects can 
Table 2: Breakdown of side effect profile
Side effects Pregnant Nonpregnant
Nightmares 5 (12.5%) 9 (22.5%)
Skin rash 2 (5.0%) 0
Skin itching 0 1 (2.5%)
Insomnia 4 (10.0%) 2 (5.0%)
Drowsiness 9 (22.5%) 9 (22.5%)
Confusion 0 4 (10.0%)
Abnormal thinking 1 (2.5%) 0
Loss of memory 0 0
Total 21 (100%) 25 (100%)
Table 3a: Cross‑tabulation between age and side effects of 





Insomnia Drowsiness Memory 
loss
Total
25‑29 2 0 0 1 0 3
Row % 66.7 0.0 0.0 33.3 0.0 100.0
30‑34 2 0 3 4 0 9
Row % 22.2 0.0 33.3 44.4 0.0 100.0
≥35 1 2 1 4 1 9
Row % 11.1 22.2 11.1 44.4 11.1 100.0
Total 5 2 4 9 1 21
Row % 100.0 9.5 16.0 36.0 4.8 100.0
Table 3b: Cross‑tabulation between age and side effects of efavirenz among nonpregnant respondents
Age (years) Nightmares Skin itching Insomnia Drowsiness Confusion Loss of memory Total
20‑24 0 0 0 1 0 0 1
Row % 0.0 0.0 0.0 100.0 0.0 0.0 100.0
25‑29 3 0 0 0 1 0 4
Row % 75.0 0.0 0.0 0.0 25.0 0.0 100.0
30‑34 0 0 0 3 0 1 4
Row % 0.0 0.0 0.0 75.0 0.0 25.0 100.0
≥35 6 1 2 5 1 1 16
Row % 37.5 6.3 12.5 31.3 6.3 6.3 100.0
Total 9 1 2 9 2 2 25
Row % 36.0 4.0 8.0 36.0 8.0 8.0 100.0
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affect compliance.[13] Nine pregnant respondents complained 
of drowsiness, five complained of nightmares, while four 
complained of insomnia as side effects of Atripla. However, 
among nonpregnant respondents, higher rate of these side 
effects was reported (62.5%).
The level of compliance with the use of Atripla in this study 
was 97.5% in both pregnant and nonpregnant respondents, 
which is greater than the accepted value of 95%.[16,17] This study 
showed improved immunological and virological outcomes 
among pregnant women on Atripla®. This can be attributed 
to the high adherence levels. This is in concert with other 
studies that have shown that adherence with HAART results 
in improved immunological and virological outcome.[18] This 
finding was also observed among nonpregnant respondents.
Some studies have shown an increased tendency of adverse 
outcome with the use of HAART when the CD4 cell count 
is ˃250 cells/mm3.[18] This study showed that pregnant 
respondents with CD4 counts ˂ 400 cells/mm3 were associated 
with the development of side effects.
This study is among the few studies that assessed the 
maternal side-effect profile of efavirenz use among pregnant 
women in a resource-constrained setting. However, it is 
limited by the small sample size, the short duration of 
evaluation, and the self-report of adherence.
In conclusion, CNS-based side effects are the predominant 
side effects associated with the use of efavirenz. However, 
with high levels of adherence improved immunological and 
virological outcome has been associated with its use. It is 
imperative for caregivers to women with HIV infection to 
understand the side effects and emphasize this to the women 
at the point of counselling on efavirenz-containing HAART use 
and provide measures to reduce them to ensure compliance.
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